Regeneron Pharmaceuticals, Inc. (REGN)
NASDAQ · Healthcare
Regeneron Pharmaceuticals, Inc. Operating Income 2008–2025
Regeneron Pharmaceuticals, Inc. annual/quarterly operating income history and growth rate from 2008 to 2026. Operating income (EBIT) is profit from core business operations, excluding interest and income taxes. It reflects the efficiency of a company's core operations.
- Regeneron Pharmaceuticals, Inc. operating income for the quarter ending March 31, 2026 was 642.9 M, a 8.65% increase year-over-year.
- Regeneron Pharmaceuticals, Inc. operating income for the twelve months ending March 31, 2026 was 3.3 B, a 18.74% decrease year-over-year.
- Regeneron Pharmaceuticals, Inc. annual operating income for 2025 was 3.6 B, a 10.34% decrease from 2024.
- Regeneron Pharmaceuticals, Inc. annual operating income for 2024 was 4.0 B, a 1.39% decrease from 2023.
- Regeneron Pharmaceuticals, Inc. annual operating income for 2023 was 4.0 B, a 14.60% decrease from 2022.
- Regeneron Pharmaceuticals, Inc. annual operating income for 2022 was 4.7 B.
Operating Income
ANNUAL · $B
QUARTERLY · $B
YEAR-OVER-YEAR GROWTH · %
Regeneron Pharmaceuticals Inc. Operating Income — FAQ
Regeneron Pharmaceuticals Inc. (REGN) operating income over the last 18 years — annual and quarterly figures with year-over-year growth and charts.
What is Regeneron Pharmaceuticals Inc.'s operating income?
Regeneron Pharmaceuticals Inc. (REGN) reported operating income of $3.58B for fiscal 2025.
Where can I see REGN's operating income history?
The chart and table above show Regeneron Pharmaceuticals Inc.'s operating income by year and by quarter, including the growth rate.